Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19)
Main Author: | |
---|---|
Publication Date: | 2021 |
Other Authors: | , , , , , , , |
Format: | Article |
Language: | eng |
Source: | Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) |
Download full: | http://hdl.handle.net/10400.18/7679 |
Summary: | Introduction: The aim of this study was to estimate and describe the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) specific antibodies (immunoglobulin M and/or immunoglobulin G) in Portugal in May-July 2020. Material and methods: A cross-sectional seroepidemiological survey was developed after the peak of the first epidemic wave on a sample of 2301 Portuguese residents, aged 1 year or older. Survey sample was selected using a two-stage stratified non-probability sampling design (quota sampling). SARS-CoV-2 immunoglobulin M and immunoglobulin G antibodies were measured in serum samples by enzyme-linked immunosorbent assay. Seroprevalence estimates of immunoglobulin M and/or immunoglobulin G and 95% confidence intervals were stratified by sex, age group, health region and education. Results: Overall, seroprevalence was 2.9% (95% confidence interval: 2.0% - 4.2%). Higher prevalence rates were observed in male (4.1%, 95% confidence interval: 2.6% - 6.6%) and those with secondary education (6.4%, 95% confidence interval: 3.2% - 12.5%). Differences in seroprevalence by age group and region were not statistically significant. Discussion: The estimated seroprevalence of SARS-CoV-2 was higher than the cumulative incidence reported by the National Surveillance System but far from necessary to reach herd immunity. Conclusion: Our results support limited extent of infection by SARS-CoV-2 in the study population possibly due to early lockdown measures implemented in Portugal and support the need to continue monitoring of SARS-CoV-2 seroprevalence in order to increase our knowledge about the evolution of the epidemic and to estimate the proportion of the susceptible population over time. |
id |
RCAP_c75658dbda684c523adb73be515ea4ba |
---|---|
oai_identifier_str |
oai:repositorio.insa.pt:10400.18/7679 |
network_acronym_str |
RCAP |
network_name_str |
Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) |
repository_id_str |
https://opendoar.ac.uk/repository/7160 |
spelling |
Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19)Seroprevalência da Infecção por SARS-CoV-2 em Portugal em maio-julho de 2020: resultados do Primeiro Inquérito Serológico Nacional (ISNCOVID-19)COVID-19Immunoglobulin GImmunoglobulin MSARS-CoV-2SeroprevelenceSurveyCOVID-19 TestingAntibodies, ViralSeroepidemiologic StudiesAnticorpos AntiviraisEstudos SeroepidemiológicosImunoglobulina GImunoglobulina MTestagem COVID-19Estados de Saúde e de DoençaPortugalIntroduction: The aim of this study was to estimate and describe the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) specific antibodies (immunoglobulin M and/or immunoglobulin G) in Portugal in May-July 2020. Material and methods: A cross-sectional seroepidemiological survey was developed after the peak of the first epidemic wave on a sample of 2301 Portuguese residents, aged 1 year or older. Survey sample was selected using a two-stage stratified non-probability sampling design (quota sampling). SARS-CoV-2 immunoglobulin M and immunoglobulin G antibodies were measured in serum samples by enzyme-linked immunosorbent assay. Seroprevalence estimates of immunoglobulin M and/or immunoglobulin G and 95% confidence intervals were stratified by sex, age group, health region and education. Results: Overall, seroprevalence was 2.9% (95% confidence interval: 2.0% - 4.2%). Higher prevalence rates were observed in male (4.1%, 95% confidence interval: 2.6% - 6.6%) and those with secondary education (6.4%, 95% confidence interval: 3.2% - 12.5%). Differences in seroprevalence by age group and region were not statistically significant. Discussion: The estimated seroprevalence of SARS-CoV-2 was higher than the cumulative incidence reported by the National Surveillance System but far from necessary to reach herd immunity. Conclusion: Our results support limited extent of infection by SARS-CoV-2 in the study population possibly due to early lockdown measures implemented in Portugal and support the need to continue monitoring of SARS-CoV-2 seroprevalence in order to increase our knowledge about the evolution of the epidemic and to estimate the proportion of the susceptible population over time.Ordem dos MédicosRepositório Científico do Instituto Nacional de SaúdeKislaya, IrinaGonçalves, PauloBarreto, MartaDe Sousa, RitaGarcia, Ana CristinaMatos, RitaGuiomar, RaquelRodrigues, Ana PaulaISNCOVID-19 group2021-04-09T15:38:45Z2021-02-012021-02-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.18/7679eng1646-075810.20344/amp.15122info:eu-repo/semantics/openAccessreponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiainstacron:RCAAP2025-02-26T14:24:34Zoai:repositorio.insa.pt:10400.18/7679Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireinfo@rcaap.ptopendoar:https://opendoar.ac.uk/repository/71602025-05-28T21:39:44.557758Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiafalse |
dc.title.none.fl_str_mv |
Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19) Seroprevalência da Infecção por SARS-CoV-2 em Portugal em maio-julho de 2020: resultados do Primeiro Inquérito Serológico Nacional (ISNCOVID-19) |
title |
Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19) |
spellingShingle |
Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19) Kislaya, Irina COVID-19 Immunoglobulin G Immunoglobulin M SARS-CoV-2 Seroprevelence Survey COVID-19 Testing Antibodies, Viral Seroepidemiologic Studies Anticorpos Antivirais Estudos Seroepidemiológicos Imunoglobulina G Imunoglobulina M Testagem COVID-19 Estados de Saúde e de Doença Portugal |
title_short |
Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19) |
title_full |
Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19) |
title_fullStr |
Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19) |
title_full_unstemmed |
Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19) |
title_sort |
Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19) |
author |
Kislaya, Irina |
author_facet |
Kislaya, Irina Gonçalves, Paulo Barreto, Marta De Sousa, Rita Garcia, Ana Cristina Matos, Rita Guiomar, Raquel Rodrigues, Ana Paula ISNCOVID-19 group |
author_role |
author |
author2 |
Gonçalves, Paulo Barreto, Marta De Sousa, Rita Garcia, Ana Cristina Matos, Rita Guiomar, Raquel Rodrigues, Ana Paula ISNCOVID-19 group |
author2_role |
author author author author author author author author |
dc.contributor.none.fl_str_mv |
Repositório Científico do Instituto Nacional de Saúde |
dc.contributor.author.fl_str_mv |
Kislaya, Irina Gonçalves, Paulo Barreto, Marta De Sousa, Rita Garcia, Ana Cristina Matos, Rita Guiomar, Raquel Rodrigues, Ana Paula ISNCOVID-19 group |
dc.subject.por.fl_str_mv |
COVID-19 Immunoglobulin G Immunoglobulin M SARS-CoV-2 Seroprevelence Survey COVID-19 Testing Antibodies, Viral Seroepidemiologic Studies Anticorpos Antivirais Estudos Seroepidemiológicos Imunoglobulina G Imunoglobulina M Testagem COVID-19 Estados de Saúde e de Doença Portugal |
topic |
COVID-19 Immunoglobulin G Immunoglobulin M SARS-CoV-2 Seroprevelence Survey COVID-19 Testing Antibodies, Viral Seroepidemiologic Studies Anticorpos Antivirais Estudos Seroepidemiológicos Imunoglobulina G Imunoglobulina M Testagem COVID-19 Estados de Saúde e de Doença Portugal |
description |
Introduction: The aim of this study was to estimate and describe the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) specific antibodies (immunoglobulin M and/or immunoglobulin G) in Portugal in May-July 2020. Material and methods: A cross-sectional seroepidemiological survey was developed after the peak of the first epidemic wave on a sample of 2301 Portuguese residents, aged 1 year or older. Survey sample was selected using a two-stage stratified non-probability sampling design (quota sampling). SARS-CoV-2 immunoglobulin M and immunoglobulin G antibodies were measured in serum samples by enzyme-linked immunosorbent assay. Seroprevalence estimates of immunoglobulin M and/or immunoglobulin G and 95% confidence intervals were stratified by sex, age group, health region and education. Results: Overall, seroprevalence was 2.9% (95% confidence interval: 2.0% - 4.2%). Higher prevalence rates were observed in male (4.1%, 95% confidence interval: 2.6% - 6.6%) and those with secondary education (6.4%, 95% confidence interval: 3.2% - 12.5%). Differences in seroprevalence by age group and region were not statistically significant. Discussion: The estimated seroprevalence of SARS-CoV-2 was higher than the cumulative incidence reported by the National Surveillance System but far from necessary to reach herd immunity. Conclusion: Our results support limited extent of infection by SARS-CoV-2 in the study population possibly due to early lockdown measures implemented in Portugal and support the need to continue monitoring of SARS-CoV-2 seroprevalence in order to increase our knowledge about the evolution of the epidemic and to estimate the proportion of the susceptible population over time. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-04-09T15:38:45Z 2021-02-01 2021-02-01T00:00:00Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10400.18/7679 |
url |
http://hdl.handle.net/10400.18/7679 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
1646-0758 10.20344/amp.15122 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Ordem dos Médicos |
publisher.none.fl_str_mv |
Ordem dos Médicos |
dc.source.none.fl_str_mv |
reponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia instacron:RCAAP |
instname_str |
FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) |
collection |
Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) |
repository.name.fl_str_mv |
Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia |
repository.mail.fl_str_mv |
info@rcaap.pt |
_version_ |
1833599368391819264 |